News | June 02, 2021
Lasa Supergenerics FY21 profit up 521%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Financial support is being provided as a grant from the Government of India
The drug accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production
The current production capacity of indigenously developed Covaxin vaccine will be doubled by May-June 2021 and then increased nearly 6-7 fold by July-August 2021.
Subscribe To Our Newsletter & Stay Updated
